Clofazimine has delayed antimicrobial activity againstMycobacterium tuberculosisbothin vitroandin vivo | Zendy

Nicole C. Ammerman | Zendy; Rosemary V. Swanson | Zendy; Asa Tapley | Zendy; Chivonne Moodley | Zendy; Bongani Ngcobo | Zendy; John Adamson | Zendy; Afton Dorasamy | Zendy; Sashen Moodley | Zendy; Zinhle Mgaga | Zendy; Linda A. Bester | Zendy; Sanil D. Singh | Zendy; Deepak V. Almeida | Zendy; J Grosset | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clofazimine has delayed antimicrobial activity againstMycobacterium tuberculosisbothin vitroandin vivo

Author(s) -

Nicole C. Ammerman,

Rosemary V. Swanson,

Asa Tapley,

Chivonne Moodley,

Bongani Ngcobo,

John Adamson,

Afton Dorasamy,

Sashen Moodley,

Zinhle Mgaga,

Linda A. Bester,

Sanil D. Singh,

Deepak V. Almeida,

J Grosset

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw417

Subject(s) - clofazimine , antimicrobial , in vivo , mycobacterium tuberculosis , pharmacology , isoniazid , microbiology and biotechnology , antibacterial agent , antibiotics , tuberculosis , medicine , in vitro , leprosy , biology , immunology , pathology , biochemistry

The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and preclinical studies of TB chemotherapy. However, a reported lack of early bactericidal activity (EBA) in TB patients has raised questions regarding the usefulness of clofazimine as an anti-TB drug. Our objective was to systematically evaluate the EBA of clofazimine in vitro and in vivo to provide insight into how and when this drug exerts its antimicrobial activity against M. tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research